Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=3&sort=awardee_organization
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=awardee_organization", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1392&sort=awardee_organization", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=4&sort=awardee_organization", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=2&sort=awardee_organization" }, "data": [ { "type": "Grant", "id": "4102", "attributes": { "award_id": "NNX16AK48G", "title": "ASTEROID 2008 TC3 WAS TRACKED AND STUDIED IN SPACE FOR ~19 HOURS BEFORE IT IMPACTED EARTH'S ATMOSPHERE AND SHATTERED OVER NORTHERN SUDAN ON OCTOBER 7, 2008.WE WILL CONDUCT PETROLOGIC STUDIES, OXYGEN ISOTOPE ANALYSES, AR-AR DATING, AND SPECTROSCOPIC MEASUR", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2016-05-23", "end_date": "2017-05-22", "award_amount": 0, "principal_investigator": { "id": 13774, "first_name": "CYRENA", "last_name": "GOODRICH", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "ASTEROID 2008 TC3 WAS TRACKED AND STUDIED IN SPACE FOR ~19 HOURS BEFORE IT IMPACTED EARTH'S ATMOSPHERE AND SHATTERED OVER NORTHERN SUDAN ON OCTOBER 7, 2008.WE WILL CONDUCT PETROLOGIC STUDIES, OXYGEN ISOTOPE ANALYSES, AR-AR DATING, AND SPECTROSCOPIC MEASUR", "keywords": [], "approved": true } }, { "type": "Grant", "id": "9536", "attributes": { "award_id": "2030139", "title": "Compounding Crises: Facing Hurricane Season in the Era of COVID-19", "funder": null, "funder_divisions": [], "program_reference_codes": [ "CK090", "RND123" ], "program_officials": [], "start_date": null, "end_date": null, "award_amount": 199890, "principal_investigator": null, "other_investigators": [], "awardee_organization": null, "abstract": "Test", "keywords": [ "covid", "research" ], "approved": true } }, { "type": "Grant", "id": "8222", "attributes": { "award_id": "75N92021C00008-0-9999-1", "title": "AWARD A CONTRACT FOR RADX TECH - QORVO TO SECURE AN EUA APPROVED POC ANTIGEN TEST SYSTEM AS WELL AS INCREASE AN INCREMENTAL DAILY CARTRIDGE PRODUCTION", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2021-04-02", "end_date": "2022-04-01", "award_amount": 24361759, "principal_investigator": { "id": 24054, "first_name": "HANJOON", "last_name": "RYU", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "Qorvo Biotechnologies’ (Qorvo) investigational Bulk Acoustic Wave (BAW) sensor detection platform (Omnia TM ) targets viral antigen testing for use in Point-of-Care (POC) settings. The platform is designed to produce reliable and quantitative results matching central lab performance and improving confidence in POC tests. Developed over a 6+ year timeframe, the technological differentiation is in the detection core, where Qorvo has optimized the BAW device that is made at low cost and high volume (millions per day for cell phones) for liquid biosensing. Detection of SARS-CoV-2 antigen occurs with a shift in the biosensor resonance frequency as antigen (Nucleocapsid and Spike S1) protein mass accumulates at specific probes on the sensor surface. Traditional optical/ fluorescence sensing is replaced by high-sensitivity, high-specificity solid-state mass-based sensing. While this proposal is focused on antigen test development, Qorvo has submitted for a SARS-CoV-2 IgG antibody test EUA on the same BAW platform that was completed in less than 10 weeks with world-class performance of 100% specificity and 100% negative cross reactivity. Given this is just one of over a dozen other assays previously run through this platform, the results give us extreme confidence in our ability to execute the viral antigen technical and timeline tasks. Qorvo has invested heavily in manufacturing infrastructure commercial development for the antibody test as well as existing veterinary and human development products so the antigen will be part of a product suite. RADx assistance will enable acceleration of regulatory and US-based high-volume manufacturing ramp.", "keywords": [ "2019-nCoV", "Acceleration", "Acoustics", "Antigens", "Biological Assay", "Biosensing Techniques", "Biosensor", "Cellular Phone", "Contracts", "Detection", "Development", "Devices", "Fluorescence", "Frequencies", "Human Development", "Immunoglobulin G", "Infrastructure", "Investigation", "Liquid substance", "Nucleocapsid", "Optics", "Performance", "Production", "Proteins", "RADx", "RADx Tech", "Ramp", "Running", "SARS-CoV-2 antigen", "Secure", "Specificity", "Surface", "System", "TimeLine", "Viral Antigens", "antibody test", "antigen test", "base", "cost", "cross reactivity", "design", "detection platform", "improved", "point of care", "point of care testing", "product development", "sensor", "solid state" ], "approved": true } }, { "type": "Grant", "id": "9115", "attributes": { "award_id": "75N92020C00010-P00001-9999-1", "title": "RADX TECH - TALIS BIOMEDICAL HIGHLY SCALABLE SARS-COV-2 RNA DETECTION IN MINUTES", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-07-30", "end_date": "2021-07-29", "award_amount": 9750000, "principal_investigator": { "id": 24901, "first_name": "JENNIFER", "last_name": "BALDWIN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "With over $100M investment by the top biotech Venture Capital funds, NIH, CARB-X, and DARPA, Talis has developed ultrafast, sensitive, scalable technology uniquely suitable for COVID-19 testing. The Talis technology performs rapid (as fast as 6 minutes) purification of SARS-CoV-2 RNA from large volumes of human specimens including swabs and saliva and detects SARS-CoV-2 RNA in under 5 minutes for high positives and under 10 minutes near the limit of detection (~10 copies/reaction). Talis will deploy this technology in a high-throughput format for laboratories (Talis HT) and at the point-of-care (POC) for minimally trained users (Talis One). With RADx support, Talis will scale this technology in three stages: (1) In June, to accelerate throughput of the currently installed diagnostic equipment, Talis will deliver reagent kits for rapid SARS-CoV-2 detection in 96-well format. (2) In July, to further increase testing throughput, Talis will launch automation solutions for common diagnostic laboratory platforms, making kits for 4 million tests available. (3) In September, Talis will launch its rapid COVID-19 Talis One POC test on a multiplexed cartridge, expandable to include influenza. Operated by a compact Talis One instrument, this cartridge enables fully automated, sensitive SARS-CoV-2 RNA detection in under 20 minutes. Talis HT and Talis One will be adaptable to mobile testing for rapid response contact tracing, worker screening, and outbreak response. Talis is requesting RADx support to scale up and accelerate manufacturing of tests and will commit significant funds for cost-sharing.", "keywords": [ "2019-nCoV", "Automation", "Biotechnology", "COVID-19", "COVID-19 detection", "COVID-19 testing", "Capital Financing", "Contact Tracing", "Cost Sharing", "Detection", "Diagnostic", "Diagnostic Equipment", "Disease Outbreaks", "Funding", "Human", "Influenza", "Investments", "Laboratories", "RADx", "RADx Tech", "RNA", "Reaction", "Reagent", "Saliva", "Specimen", "Swab", "Technology", "Testing", "Training", "United States National Institutes of Health", "detection limit", "instrument", "point of care", "point of care testing", "rapid testing", "response", "scale up", "screening" ], "approved": true } }, { "type": "Grant", "id": "11681", "attributes": { "award_id": "1U01DA057849-01", "title": "Supported employment to create a community culture of SARS-CoV-2 rapid testing among people who inject drugs: PeerConnect2Test", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": null, "end_date": null, "award_amount": null, "principal_investigator": { "id": 26966, "first_name": "Camille C", "last_name": "Cioffi", "orcid": "https://orcid.org/0000-0003-2424-7473", "emails": "[email protected]", "private_emails": null, "keywords": "[]", "approved": true, "websites": "['psi.uoregon.edu']", "desired_collaboration": "", "comments": "", "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "", "keywords": [], "approved": true } }, { "type": "Grant", "id": "6681", "attributes": { "award_id": "75N92021C00018-P00002-9999-1", "title": "RADX TECH 2375 - POINT OF NEED, SALIVA-BASED, COVID-19 TESTING PLATFORMS", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2021-07-01", "end_date": "2022-06-30", "award_amount": 12970000, "principal_investigator": { "id": 22379, "first_name": "DAVE", "last_name": "BEEBE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "The key conceptual insight underpinning this proposal is that detecting individuals who are most likely to transmit SARS-CoV-2 is essential to mitigating the pandemic and reopening America. Our approach consciously contrasts with most existing nucleic acid testing platforms, which begin from the premise that maximizing detection sensitivity is the goal. We argue that striving for maximum sensitivity is at odds with the current needs for broad population based testing and that in a public health emergency, nucleic acid testing should be designed to maximize the number of people who can be tested for high viral loads consistent with shedding of live virus, in the greatest number of settings, at the lowest possible cost. To achieve this we couple a proven, ultrafast nucleic acid extraction method with rapid detection of amplified nucleic acids in an assay that can be both massively scaled in centralized reference labs and also used by point-of-care testing providers. The key enabling technology is a new, but proven, nucleic acid extraction method that reliably, quickly, and easily extracts, purifies, and concentrates viral RNA from a variety of sample types including nasal swabs and saliva in a highly parallel format. RNA prepared using this extraction method can be reliably amplified and detected using a simple colorimetric assay following isothermal amplification. These two technologies combined provide a testing platform that can enable millions of tests a week, at low cost, in both centralized laboratories and at point-of-care using technicians with no specialized training to support test/isolate/trace.", "keywords": [ "Americas", "Biological Assay", "COVID-19 testing", "Conscious", "Goals", "Individual", "Laboratories", "Methods", "Nucleic Acid Amplification Tests", "Nucleic Acids", "Persons", "Provider", "RADx Tech", "RNA", "SARS-CoV-2 transmission", "Saliva", "Sampling", "Technology", "Testing", "Training", "Viral Load result", "Virus", "amplification detection", "base", "cost", "design", "detection sensitivity", "insight", "isothermal amplification", "nasal swab", "pandemic disease", "point of care", "point of care testing", "population based", "public health emergency", "rapid detection", "viral RNA" ], "approved": true } }, { "type": "Grant", "id": "8098", "attributes": { "award_id": "75N92021C00003-0-9999-1", "title": "RAPID ACCELERATION OF DIAGNOSTICS (RADX) TECH PROJECT #6139: REVOGENE SARS-COV-2 ASSAY", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2021-02-01", "end_date": "2022-01-31", "award_amount": 5505000, "principal_investigator": { "id": 23980, "first_name": "TODD", "last_name": "WOODRICH", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "Resubmission of Application 3136. This product concept has been updated to include Flu viral targets along with SARS-CoV-2. The Rapid Acute Respiratory Panel assay will be a molecular IVD assay practiced on an already deployed automated Revogene instrument which currently has 4 infectious disease FDA cleared assays. The intended use will be to detect the Flu A, Flu B and SARS-CoV-2 viruses from nasopharyngeal specimens collected from symptomatic patients suspected of viral infection. This will be a multiplexed viral panel for the differentiation of Flu from SARS-CoV-2 patients which will be of high clinical value in our upcoming Flu season 2020-2021. We plan to launch this assay with EUA status by October 2020. The assay will detect RNA sequences for these viral targets using PCR amplification technology coupled with real-time flourescence detection similar to our FDA cleared assays. The workflow is automated where the user will need to add the specimen to the assay consumable prior to loading on the instrument. The Revogene platform contains the necessary software to run the assay and report out positive/negative results. This assay is of very low complexity to practice with no precision pipetting steps and is eligible for CLIA waiver status. We currently have an installment base of instruments in the field where this assay will be practiced. For this product concept, we will need your assistance in discussing this concept with the FDA to allow us to gain EUA and CLIA waiver status especially for the Flu A/B targets in the panel.", "keywords": [ "2019-nCoV", "Acute", "Biological Assay", "COVID-19 assay", "COVID-19 patient", "Clinical", "Communicable Diseases", "Computer software", "Coupled", "Detection", "Molecular", "Patients", "RADx Tech", "RNA Sequences", "Reporting", "Running", "Seasons", "Specimen", "Technology", "Time", "Update", "Viral", "Virus", "Virus Diseases", "base", "betacoronavirus", "flu", "instrument", "respiratory", "waiver" ], "approved": true } }, { "type": "Grant", "id": "8122", "attributes": { "award_id": "75N92021C00009-0-9999-1", "title": "RADX TECH XTRAVA, INC. - SPERA COVID-19 AG TESTRAPID ACCELERATION OF DIAGNOSTICS (RADX) PROGRAM: TECH PROJECT #5834 XTRAVA, INC.", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2021-03-04", "end_date": "2022-03-03", "award_amount": 6207000, "principal_investigator": { "id": 23997, "first_name": "SAMEH", "last_name": "SARHAN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "Mitigating the economic and health challenges of COVID-19 is hindered by the absence of mass population testing. Available platforms are designed for lab-use and rely on sophisticated technologies and readers. They are slow, expensive, hard to manufacture and overload healthcare professionals with time consuming manual workflows; presenting massive obstacles to high throughput testing. We introduce a novel platform to diagnose COVID-19, which includes a digital test that combines fluorescent lateral flow assays with our patent-pending cost-optimized lateral flow test platform which was initially developed to detect H1N1. We have formed the essential alliances with key partners to rapidly scale up manufacturing and distribution to the points-of-need. Nasal swabs (and soon saliva samples) are tested in under 15 minutes. The digital results are wirelessly communicated to the participants’ mobile devices and the cloud thereby providing healthcare providers with test status and sharing real-time analytics and monitoring capabilities with health authorities. In the first stage, the test will be deployed into CLIA-waived point-of-care clinics, walk-in facilities and drive-thru testing centers for less than $35 for the digital test and with an effective cost of less than $10 per disposable test. After full validation, we will immediately extend deployment to at-home use by leveraging machine vision-guided self-testing. By combining IoT technologies that are proven to enable large-scale production with rapid diagnostic testing we believe we are uniquely positioned to increase testing throughput by 10X-100X. RADx re-enforcement will propel the launch of the system in highly condensed timeframes to meet the enormous need.", "keywords": [ "Acceleration", "COVID-19", "COVID-19 diagnosis", "Clinic", "Consumption", "Diagnostic", "Diagnostic tests", "Economics", "Health", "Health Personnel", "Health Professional", "Home", "Influenza A Virus H1N1 Subtype", "Legal patent", "Manuals", "Monitor", "Population", "Positioning Attribute", "RADx", "RADx Tech", "Rapid diagnostics", "Reader", "System", "Technology", "Testing", "Time", "Validation", "Walking", "Wireless Technology", "authority", "cost", "design", "digital", "handheld mobile device", "large scale production", "lateral flow assay", "machine vision", "manufacturing scale-up", "nasal swab", "novel", "point of care", "programs", "saliva sample", "self testing" ], "approved": true } }, { "type": "Grant", "id": "9299", "attributes": { "award_id": "75N92020C00033-P00001-9999-1", "title": "RADX TECH PROJECT #4554: UBIQUITOME SARS-COV-2 LAB TEST ACCURACY WITHIN REACH OF EVERY AMERICAN WITH LIBERTY16 MOBILE REAL TIME PCR", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-09-29", "end_date": "2021-09-28", "award_amount": 1760000, "principal_investigator": { "id": 25039, "first_name": "PAUL", "last_name": "PICKERING", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "Gold standard SARS-CoV-2 testing (100% specificity, 100% sensitivity) has been available in America February 4, 2020, through the FDA CDA real time PCR test, yet it is still not available to many Americans who need it. Recent attempts to make SARS-CoV-2 testing more accessible (e.g. Abbott & Quidel) has been plagued by low throughput (single sample at a time) and high false negatives. What is needed is the CDC’s FDA authorized gold standard real time PCR testing within reach of every American. We propose to engage in a rapid enhancement and scaling program for our commercial mobile Liberty16 system that will allow this fully mobile real time PCR device to exceed the throughput- based gold standard 96-well based workflows in centralized labs while offering the same low false negative levels (<5%) observed with the CDC test. Enhanced Functionality. We will fast-track implemetation of several planned features that substantially enhance the throughput and user interface of the exisiting Liberty16 system: (1) Implementation of multiplex capability enabling single-well detection of multiple targets. This increases sample capacity from 3 to 14 (plus controls) per run. (2) Implementation of software and minor hardware modifications that significantly reduce the run time from 40 minutes to 25 minutes or less. (3) Update the Liberty16 iPhone/iPad user interface to include (i) a barcode reader for sample identifier input; (ii) automated reporting of multiplexed assays. (4) Optimize a safe sample collection and preparation workflow for saliva, enabling setup completion in under 5 minutes and with minimal processing steps.", "keywords": [ "2019-nCoV", "American", "Americas", "Bar Codes", "COVID-19 testing", "Cellular Phone", "Centers for Disease Control and Prevention (U.S.)", "Computer software", "Detection", "Devices", "Gold", "Minor", "Modification", "Preparation", "RADx Tech", "Reader", "Reporting", "Running", "Saliva", "Sampling", "Specificity", "System", "Testing", "Time", "Update", "base", "multiplex assay", "programs", "sample collection" ], "approved": true } }, { "type": "Grant", "id": "5124", "attributes": { "award_id": "NNX10AR42G", "title": "We propose a set of two 19 arcmin offset observations for the galaxy group MKW 4 to measure spatially resolved density, temperature and iron abundance out to 1''500, These measurements are crucial for an accurate determination of the gas mass profile and", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2011-01-01", "end_date": "2012-12-31", "award_amount": 0, "principal_investigator": { "id": 18257, "first_name": "DAVID", "last_name": "BUOTE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1407, "ror": "", "name": "REGENTS OF THE UNIVERSITY OF CALIFORNIA THE (6406)", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": null, "abstract": "We propose a set of two 19 arcmin offset observations for the galaxy group MKW 4 to measure spatially resolved density, temperature and iron abundance out to 1''500, These measurements are crucial for an accurate determination of the gas mass profile and", "keywords": [], "approved": true } } ], "meta": { "pagination": { "page": 3, "pages": 1392, "count": 13920 } } }